Biotech Values

[urche]

EXEL

Is it known whether the other 2 patients among the 10 responders had a follow-up scan?

After re-reading your astute question and the available PR and poster abstract, I think the phrasing in the PR is ambiguous and I probably interpreted it erroneously initially.

From the description of the study design and the poster, it is apparent that the actual study was limited to 6 weeks of CABO treatment.
So, the data reported on the group that went out to 12 weeks was not part of the original study, and is not referred to at all in the poster presentation.
Therefore, I don't think we have the available context to interpret the fact that only 8 of 10 six week responders could be "confirmed" at 12 weeks. This could mean two patients stopped responding but, more likely, that two patients just were not followed beyond the initial 6 wks for any number of reasons.

Once again, here is the relevant snip from the PR:

Twelve patients were enrolled in the 40 mg cohort. One of the these patients discontinued the study at Week 2 due to worsening of pre-existing anorexia and fatigue, and another patient discontinued at Week 6 after experiencing a pathologic hip fracture. Eleven patients were evaluable at Week 6, of which 10 had bone scan responses. The median decrease in bone scan lesion area was 61.5%. Eight of the 10 responding patients had a confirmation of the bone scan response at week 12 and continue on treatment with a median duration of treatment of 19 weeks.